Helen brings more than 20 years of investor and operator experience in healthcare and life sciences as a Partner at BOLD. Previously, Helen spent more than thirteen years developing therapeutics in Inflammation and Oncology within Amgen’s R&D organization and later led translational sciences at an oncology start-up, TORL Biotherapeutics. As an investor, Helen led healthcare investing for several years for the Fund@Caltech, a seed-stage fund supporting multiple successful spinouts from the Institute. Helen received her BS degree in Microbiology from Texas A&M University, her PhD in Oncological Sciences from the University of Utah, and her postdoctoral training at Caltech studying developmental neurobiology and biophysics.